Bionano Genomics Balance Sheet Health
Financial Health criteria checks 6/6
Bionano Genomics has a total shareholder equity of $214.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $271.4M and $56.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$77.06m |
Equity | US$214.76m |
Total liabilities | US$56.63m |
Total assets | US$271.38m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 2Y30's short term assets ($122.6M) exceed its short term liabilities ($33.5M).
Long Term Liabilities: 2Y30's short term assets ($122.6M) exceed its long term liabilities ($23.1M).
Debt to Equity History and Analysis
Debt Level: 2Y30 is debt free.
Reducing Debt: 2Y30 currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2Y30 has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 2Y30 is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.